Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLP COVID-19 vaccine (Saiba Biotech)
- Development stage
- Preclinical
- Lead developer
- Saiba
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VLP COVID-19 vaccine (Saiba Biotech) is a preclinical vaccine candidate developed to prevent COVID-19. It utilizes Saiba Biotech's proprietary virus-like particle (VLP) platform to display SARS-CoV-2 antigens, such as the spike protein or its receptor-binding domain (RBD), in a highly repetitive and organized array. This structure mimics the physical form of the actual virus, which effectively stimulates the immune system to produce high titers of neutralizing antibodies and activate robust T-cell responses without the risk of infection. The development of this vaccine involves collaborations with several prominent institutions, including the University of Zurich, the Jenner Institute at the University of Oxford, ETH Zurich, and A*STAR Singapore.
- Other names
- SARS-CoV-2 VLP vaccineSARS-CoV2 VLP vaccineSARS-CoV 2 VLP vaccineSARS-CoV-2 VLP-based vaccineSARS-CoV2 VLP-based vaccineSARS-CoV 2 VLP-based vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on VLP COVID-19 vaccine (Saiba Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLP COVID-19 vaccine (Saiba Biotech).